HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EWG Remains Concerned About SPF Boosting With Anti-Inflammatories

This article was originally published in The Rose Sheet

Executive Summary

Without an FDA cap on SPF claims, companies continue to answer consumer demand for lofty SPFs using the limited active ingredients cleared for OTC use in the US. The Environmental Working Group says manufacturers also are spiking sunscreen formulas with anti-inflammatory ingredients to boost SPF scores, but some such ingredients may only "mask" signs of UV-induced skin damage.

You may also be interested in...



FDA Clears Outdated Sunscreen Petitions From Queue With Trio Of Denials

The agency refers L’Oreal, Shiseido’s Bare Escentuals and Rapid Precision Testing Laboratories to its newly proposed sunscreen rule, which covers most of the points raised in their petitions. Seeking GRASE status for powder dosage forms and higher concentrations of avobenzone, among other asks, the rejected citizen petitions trace back as far as a decade.

Consumer Reports Blasts SPF Claims Again, But Industry's Problems May Be Bigger

The annual bad marks given to sunscreen brands from Consumer Reports for their SPF claims could be due to CR's nonconformity with FDA-prescribed test guidelines or could signal testing failures or other compliance problems in the industry. In any event, companies are hurrying to retest sunscreen formulas and validate their claims.

Could Gottlieb Bring Red-Tape Scissors To FDA Sunscreen Review?

FDA Commissioner nominee Scott Gottlieb has been a vocal critic of FDA bureaucracy and excessive data demands that in his view have slowed access to life-saving drugs and medical devices in the US. His expected confirmation as FDA head could offer a new glimmer of hope to sponsors seeking GRASE status for next-generation UV filters, a process that has all but ground to a halt, according to industry advocates.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel